In 2023, for the first time in history, a human being received an officially approved medicine that rewrites their own DNA. It treats sickle cell disease, a condition that has broken lives for centuries. The price of the course is roughly $2.2 million. The technology to erase inherited pain now exists. The question this piece is actually about isn't whether the genome can be fixed — it can. It's who holds the key to the workshop where that happens.
From Discovery to Commodity
CRISPR-Cas9, the molecular scissors precise enough to cut and paste fragments of DNA with an accuracy unthinkable twenty years ago, was worked out by Jennifer Doudna and Emmanuelle Charpentier. They won the Nobel Prize in Chemistry for it in 2020. The mechanism itself was borrowed from bacteria, which have used it for millennia to fight off viruses — nature already owned the tool; humans just learned to read the manual.
What happened next is the predictable part of the story: the discovery became property. A years-long patent war broke out between the University of California, Berkeley (Doudna's lab) and the Broad Institute of MIT and Harvard, over who first applied the technique to human and animal cells rather than test tubes alone. The US Patent Office ruled in the Broad's favor more than once, the dispute stretched past a decade, and it spawned a whole parallel universe of licensing deals. Out of that war grew companies — Editas Medicine, Intellia Therapeutics, CRISPR Therapeutics, Beam Therapeutics — each with a patent portfolio and a line of investors. A discovery made on university grants turned into a publicly traded asset.
The Price of the Cure
Take Casgevy, a CRISPR-based therapy that UK and US regulators approved within weeks of each other in late 2023, for sickle cell disease and beta-thalassemia. It was developed by Vertex Pharmaceuticals together with CRISPR Therapeutics. The procedure is brutal: bone marrow is extracted, cells are edited outside the body, then reinfused after chemotherapy wipes out the old marrow. But it works — in clinical trials, the overwhelming majority of patients were freed from the pain crises that had defined their entire lives.
Now the price: around $2.2 million for the course, one of the most expensive therapies in the history of medicine. Sickle cell disease disproportionately affects people of African descent, often in countries and communities where that sum isn't just unaffordable — it's absurd as a unit of measurement. The technology exists. Access to it doesn't. That is not a side effect of progress. It is a market structure in which the right to fix your own body is sold retail, by a company that owns the patent on the process.
Designer Children, and the Line One Man Already Crossed
In 2018, Chinese scientist He Jiankui announced he had created the world's first gene-edited babies — twin girls whose embryos he altered with CRISPR in an attempt to make them resistant to HIV. The global scientific community did not respond with applause but with shock: the experiment broke nearly every unwritten rule of bioethics, was carried out without proper oversight, and the health consequences of the edit for the children and their future descendants are unknown and will stay unknown for decades. He Jiankui served prison time in China and was released in 2022 — and has since spoken about wanting to return to embryo-editing research.
Formally, germline editing — changes that get passed down to offspring — is banned or under strict moratorium almost everywhere. But that moratorium rests on international consensus, not a physical barrier: the technology itself has grown cheap enough to fit inside a mid-tier lab. The line between "cure a disease in an embryo" and "select height, eye color, or intelligence in a future child" isn't technical. It's political and economic. And the moment such a procedure carries a price tag, Casgevy's story already tells you who gets access to "enhancement" first — not by merit, but by bank balance.
The Data Inside You
There's a quieter, less dramatic layer of control here too: not editing, but collection. Consumer genetic-testing companies — the largest being 23andMe — built genetic profiles of millions of people on the promise of telling them about their ancestry and health risks. In 2023, hackers accessed the data of roughly 6.9 million users through a credential-stuffing breach. A year later, the company itself teetered on the edge of bankruptcy — and suddenly the genetic database of millions of people became an asset that could be sold, resold, or absorbed into a restructuring.
Your genome isn't just medical information. It's a map of your relatives, your predispositions, your future risks — data an insurer, an employer, or a government might one day want to buy. Laws like the US GINA act ban discrimination based on genetic data in hiring and health insurance, but don't cover life insurance, disability insurance, or long-term care. The gaps in the law are exactly where the market will grow.
Our record: in the Maat system, Ren — the true name of a thing — isn't a label. It's the essence itself, and to hold a thing's Ren is to hold power over it. The genome is the Ren of the body in the most literal, chemical sense: the string that determines what you are at the cellular level. Isfet here isn't that someone learned to read that string, or even to rewrite it. It's that the right to read and rewrite another person's Ren became a commodity with a price list — affordable to a handful, not owed to every person by right of birth.
Who Holds It
The picture pulls into a familiar shape: a handful of biotech companies with patent portfolios (Vertex, CRISPR Therapeutics, Intellia, Editas, Beam), the university labs those companies grew out of, and a growing "biofoundry" industry — companies like Ginkgo Bioworks — that sell the very capacity to design living organisms as a subscription service to business and governments. Running alongside it is an older story: control over seeds and plant patents that agrochemical giants like Monsanto (now part of Bayer) have held for decades — a preview of the same principle now applied to the human body. Whoever holds the patent on the code of life holds the lever over who gets that code repaired first, and who never does.
There's no convenient villain in a black mask here. There's a structure: a discovery made on public money, fenced off by a private patent, monetized at a price only a handful can pay. A technology capable of removing inherited pain from the entire species is, for now, available mostly to those who already had privilege before it was invented. That is Isfet in a new costume — not banning progress, but claiming the right to decide how its fruits get distributed.
Gene editing isn't going to stop, and it shouldn't — it's already saving real people from real pain. The question worth holding onto the next time you read another optimistic headline about it: is the circle of people who get to repair their own Ren widening, or will it stay permanently the size of the first investors' bank accounts.